Article
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
JAMA oncology - 1 Aug 2022
Ricciuti Biagio, Wang Xinan, Alessi Joao V, Rizvi Hira, Mahadevan Navin R, Li Yvonne Y, Polio Andrew, Lindsay James, Umeton Renato, Sinha Rileen, Vokes Natalie I, Recondo Gonzalo, Lamberti Giuseppe, Lawrence Marissa, Vaz Victor R, Leonardi Giulia C, Plodkowski Andrew J, Gupta Hersh, Cherniack Andrew D, Tolstorukov Michael Y, Sharma Bijaya, Felt Kristen D, Gainor Justin F, Ravi Arvind, Getz Gad, Schalper Kurt A, Henick Brian, Forde Patrick, Anagnostou Valsamo, Jänne Pasi A, Van Allen Eliezer M, Nishino Mizuki, Sholl Lynette M, Christiani David C, Lin Xihong, Rodig Scott J, Hellmann Matthew D, Awad Mark M
Abstract excerpt
Importance: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about the optimal TMB threshold that best discriminates improved outcomes of immune checkpoint inhibitor therapy among patients with non-small cell lung cancer (NSCLC). Objectives: To determine the association between increasing TMB levels and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.